Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease-Reference-Cited by-同舟云学术

Antibody durability 6 months after two doses of SARS-CoV-2 mRNA vaccines in patients with rheumatic and musculoskeletal disease

Published:2022-04 Issue:4 Volume:4 Page:e241-e243
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Frey Sarah,Chiang Teresa Po-Yu,Connolly Caoilfhionn M,Teles Mayan,Alejo Jennifer L,Boyarsky Brian J,Christopher-Stine Lisa,Werbel William A,Massie Allan B,Segev Dorry L,Paik Julie J

Funder

National Institute of Allergy and Infectious Diseases

National Institute of Diabetes and Digestive and Kidney Diseases

National Institute of Arthritis and Musculoskeletal and Skin Diseases

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference7 articles.

1. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19;Doria-Rose;N Engl J Med,2021

2. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases;Ruddy;Ann Rheum Dis,2021

3. Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination;Frey;Lancet Rheumatol,2021

4. Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation;Higgins;J Clin Microbiol,2021

5. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection;Khoury;Nat Med,2021

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of treatment with original or biosimilar adalimumab on SARS-CoV2 vaccination antibody titers;International Journal of Pharmaceutics: X;2024-06

2. Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination;Blood Neoplasia;2024-03

3. Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases;The Journal of Infectious Diseases;2023-08-01

4. Long follow-up of BNT162b2 mRNA vaccine in healthcare workers (2020–2022): A retrospective longitudinal SARS-CoV-2 serological surveillance;Human Vaccines & Immunotherapeutics;2023-08

5. Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy;Frontiers in Immunology;2023-05-02